Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25547182 | 0.88 | ALDH1A1 (0.36) | ALDH1A1FFAR3 | |
| SCHEMBL4973914 | 0.86 | GAA (0.47) | PKMRAB9AGAALMNAMAPT | |
| SCHEMBL6130353 | 0.84 | GAA (0.46) | PKMRAB9AGAALMNAMAPT | |
| SCHEMBL16118626 | 0.84 | GAA (0.44) | PKMRAB9AGAALMNAMAPT | |
| SCHEMBL14003882 | 0.81 | PKM (0.43) | PKMRAB9AGAALMNAMAPT | |
| SCHEMBL301039 | 0.79 | PKM (0.59) | PKMRAB9ATSHRHSD17B10ALDH1A1 | |
| SCHEMBL2745710 | 0.77 | PKM (0.56) | PKMRAB9ATSHRHSD17B10ALDH1A1 | |
| SCHEMBL4879234 | 0.77 | EPHX2 (0.48) | TSHREPHX2 | |
| SCHEMBL13738157 | 0.77 | — | — | |
| SCHEMBL1074030 | 0.77 | GAA (0.41) | PKMRAB9AGAALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | SCHREINER PETER R | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275112-A1 | Invention Concerning Aminoadamantane Compounds | GABRA5, GABRA1, GABRA4 | PKM 2313/4885RAB9A 1398/4885GAA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.